Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

The need for a highly efficacious vaccine against Plasmodium falciparum remains pressing. In this controlled human malaria infection (CHMI) study, we assessed the safety, efficacy and immunogenicity of a schedule combining 2 distinct vaccine types in a staggered immunization regimen: one inducing hi...

Bibliografski detalji
Glavni autori:	Rampling, T, Ewer, KJ, Bowyer, G, Bliss, CM, Edwards, NJ, Wright, D, Payne, RO, Venkatraman, N, de Barra, E, Snudden, CM, Poulton, ID, de Graaf, H, Sukhtankar, P, Roberts, R, Ivinson, K, Weltzin, R, Rajkumar, BY, Wille-Reece, U, Lee, CK, Ockenhouse, CF, Sinden, RE, Gerry, S, Lawrie, AM, Vekemans, J, Morelle, D, Lievens, M, Ballou, RW, Cooke, GS, Faust, SN, Gilbert, S, Hill, AV
Format:	Journal article
Jezik:	English
Izdano:	Oxford University Press 2016

Slični predmeti

Safety and Efficacy of Novel Malaria Vaccine Regimens of RTS,S/AS01B alone, or with Concomitant ChAd63-MVA Vectored Vaccines Expressing ME-TRAP
od: Rampling, T, i dr.
Izdano: (2018)

Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP
od: Rampling, T, i dr.
Izdano: (2016)

CXCR3+ T follicular helper cells induced by co-administration of RTS,S/AS01B and viral vectored vaccines are associated with reduced immunogenicity and efficacy against Malaria
od: Ewer (nee Russell), K, i dr.
Izdano: (2018)

RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype
od: Nielsen, C, i dr.
Izdano: (2018)

A monovalent chimpanzee adenovirus Ebola vaccine — preliminary report
od: Rampling, T, i dr.
Izdano: (2015)

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
od: John N Waitumbi, i dr.
Izdano: (2009-11-01)

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
od: Bliss, C, i dr.
Izdano: (2018)

THE RTS,S MALARIA VACCINE What is the efficacy of the RTS,S malaria vaccine?
od: Duncan, C, i dr.
Izdano: (2011)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
od: Ewer (nee Russell), K, i dr.
Izdano: (2016)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
od: Ewer (nee Russell), K, i dr.
Izdano: (2017)

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
od: Bejon, P, i dr.
Izdano: (2008)

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa
od: Macete Eusebio, i dr.
Izdano: (2011-08-01)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
od: Katie Ewer, i dr.
Izdano: (2017-12-01)

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.
od: Bertrand Lell, i dr.
Izdano: (2009-10-01)

RTS,S: the first malaria vaccine
od: Fidel Zavala
Izdano: (2022-01-01)

Correction: Randomized Controlled Trial of RTS,S/AS02 and RTS,S/AS01 Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children.
od: Seth Owusu-Agyei, i dr.
Izdano: (2010-01-01)

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
od: Seth Owusu-Agyei, i dr.
Izdano: (2009-10-01)

What is the efficacy of the RTS,S malaria vaccine?
od: Duncan, C, i dr.
Izdano: (2011)

What is the efficacy of the RTS,S malaria vaccine?
od: Duncan, C, i dr.
Izdano: (2011)

RTS,S/AS01 vaccine (Mosquirix™): an overview
od: Matthew B. Laurens
Izdano: (2020-03-01)

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi
od: Griffin J. Bell, i dr.
Izdano: (2020-06-01)

Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).
od: Selidji T Agnandji, i dr.
Izdano: (2011-04-01)

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children
od: Olotu, A, i dr.
Izdano: (2014)

T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children.
od: Daniel Ansong, i dr.
Izdano: (2011-04-01)

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
od: Lusingu, J, i dr.
Izdano: (2010)

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
od: Olotu, A, i dr.
Izdano: (2011)

Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
od: Pedro Aide, i dr.
Izdano: (2010-11-01)

RTS,S/AS01 malaria vaccine in African children.
od: Hill, A
Izdano: (2012)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
od: Hodgson, SH, i dr.
Izdano: (2014)

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.
od: Lievens, M, i dr.
Izdano: (2011)

PHASE IIB, RANDOMIZED, DOUBLE-BLIND TRIAL TO ASSESS THE EFFICACY, SAFETY AND IMMUNOGENICITY OF THE CANDIDATE MALARIA VACCINE RTS,S/AS01 IN KENYAN AND TANZANIAN CHILDREN
od: Bejon, P, i dr.
Izdano: (2008)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01 in 5 to 17 Month Old Kenyan and Tanzanian Children.
od: John Lusingu, i dr.
Izdano: (2010-01-01)

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
od: John Lusingu, i dr.
Izdano: (2010-11-01)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01 in 5 to 17 Month Old Kenyan and Tanzanian Children.
od: John Lusingu, i dr.
Izdano: (2010-01-01)

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.
od: Bejon, P, i dr.
Izdano: (2011)

The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection
od: White, M, i dr.
Izdano: (2013)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
od: Rampling, T, i dr.
Izdano: (2015)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
od: Mensah, V, i dr.
Izdano: (2017)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
od: Aroosa Younis Nadeem, i dr.
Izdano: (2022-04-01)

The RTS,S malaria vaccine: Journey from conception to recommendation
od: Oluwaseyi Muyiwa Egbewande
Izdano: (2022-12-01)